title: Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma.
abstract: The increased incidence of Kaposi's sarcoma (KS) in organ transplantation has been related to the KS herpes virus and the permissive effect of immunosuppressive therapy. We postulated that conversion to SRL in renal recipients with KS favored regression of KS lesions without increasing the risk of graft rejection.
  
  
  METHODS
  In this study we performed a retrospective chart review of 7 caucasian renal transplant recipients affected by KS to determine demographic data, etiology of ESRD, immunologic risk factors, immunosuppressive treatment, KS disease follow-up, and renal function before and after SRL conversion.
  
  
  RESULTS
  All seven patients were under calcineurin inhibitor treatment at the onset of KS which was limited to the skin, without regression despite attempts to minimize immunosuppression. After conversion to SRL, six patients showed progressive regression of KS lesions, with only hyperpigmented atrophic cutaneous lesions remaining after a mean time of 8.1 months (2-18 months). The seventh patient has completed 9 months follow-up with a near complete regression of KS lesions. One patient returned to hemodialysis after 13 months following irreversible acute renal failure not directly related to SRL conversion; in the other six, renal function was stable. The mean serum creatinine was 1.87 +/- 0.64 versus 1.74 +/- 0.68 mg/dL, pre-conversion versus the end of follow up, respectively. Mean SRL blood level was 9.2 +/- 2.0 ng/mL.
  
  
  CONCLUSIONS
  After SRL conversion, patients with KS showed progressive regression without an increased risk of acute rejection. SRL offers a promising approach to the management of posttransplantation KS and probably other malignancies in organ transplant recipients.
authors.affiliation: Department of Nephrology and Renal Transplant Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain. adalmau@clinic.ub.es
authors.forename: A
authors.initials: A
authors.lastname: Gutiérrez-Dalmau
authors.forename: A
authors.initials: A
authors.lastname: Sánchez-Fructuoso
authors.forename: A
authors.initials: A
authors.lastname: Sanz-Guajardo
authors.forename: A
authors.initials: A
authors.lastname: Mazuecos
authors.forename: A
authors.initials: A
authors.lastname: Franco
authors.forename: M C
authors.initials: MC
authors.lastname: Rial
authors.forename: P
authors.initials: P
authors.lastname: Iranzo
authors.forename: J V
authors.initials: JV
authors.lastname: Torregrosa
authors.forename: F
authors.initials: F
authors.lastname: Oppenheimer
authors.forename: J M
authors.initials: JM
authors.lastname: Campistol
mesh_terms: D000818:Animals; D065095:Calcineurin Inhibitors; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012514:Sarcoma, Kaposi / Q000276:immunology*; D020123:Sirolimus / Q000627:therapeutic use*
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D020123:Sirolimus